| Literature DB >> 31216476 |
Bengt Phung1, Maciej Cieśla2, Adriana Sanna1, Nicola Guzzi2, Giulia Beneventi2, Phuong Cao Thi Ngoc2, Martin Lauss1, Rita Cabrita1, Eugenia Cordero3, Ana Bosch1, Frida Rosengren1, Jari Häkkinen1, Klaus Griewank4, Annette Paschen4, Katja Harbst1, Håkan Olsson1, Christian Ingvar5, Ana Carneiro6, Hensin Tsao7, Dirk Schadendorf4, Kristian Pietras3, Cristian Bellodi8, Göran Jönsson9.
Abstract
The X-linked DDX3X gene encodes an ATP-dependent DEAD-box RNA helicase frequently altered in various human cancers, including melanomas. Despite its important roles in translation and splicing, how DDX3X dysfunction specifically rewires gene expression in melanoma remains completely unknown. Here, we uncover a DDX3X-driven post-transcriptional program that dictates melanoma phenotype and poor disease prognosis. Through an unbiased analysis of translating ribosomes, we identified the microphthalmia-associated transcription factor, MITF, as a key DDX3X translational target that directs a proliferative-to-metastatic phenotypic switch in melanoma cells. Mechanistically, DDX3X controls MITF mRNA translation via an internal ribosome entry site (IRES) embedded within the 5' UTR. Through this exquisite translation-based regulatory mechanism, DDX3X steers MITF protein levels dictating melanoma metastatic potential in vivo and response to targeted therapy. Together, these findings unravel a post-transcriptional layer of gene regulation that may provide a unique therapeutic vulnerability in aggressive male melanomas.Entities:
Keywords: DDX3X; IRES; MITF; melanocyte; melanoma; metastasis; migration; resistance; therapy; translation control
Year: 2019 PMID: 31216476 DOI: 10.1016/j.celrep.2019.05.069
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423